Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-01-27

Clinical Trial Update: Phase 2b Challenge Study With the Bioconjugate Vaccine Flexyn2a [Phase 2]

View source ↗

Summary

Phase 2b trial of the bioconjugate vaccine Flexyn2a for Shigellosis completed; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Flexyn2a

Snippet

Sponsor: LimmaTech Biologics AG | Conditions: Shigellosis | Phase 2 | Status: COMPLETED | Results posted: 2021-01-27